Highmark Health's VITAL Innovation Program testing benefits of Biocept's liquid biopsy platform for improving outcomes and lowering costs of treatment for patients with non-small cell lung cancer
A test-and-learn platform, the unique VITAL program leverages
More than 100 patients of
Lung cancer is the leading cause of cancer death for both men and women in
Despite these advances, a large percentage of patients may not undergo molecular profiling due to a number of practical constraints. Chief among these is the availability of tissue for molecular testing. Lung cancers are often difficult to biopsy because of their location within what is often diseased lung tissue of elderly patients. Needle biopsy is the most common technique but often does not yield enough tissue for molecular testing. Performing a second biopsy is a way of remedying this situation, but these procedures can add to risk and cost. The VITAL test will study the opportunity for
"The diagnosis, treatment and care of cancer patients is among
"This project directly supports the
"This collaboration with the VITAL Innovation Program and Allegheny Health Network reflects
VITAL's evaluation of
About Allegheny Health Network
Allegheny Health Network, a
Forward-Looking Statements Disclaimer Statement
This news release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although
 Siegel RL, Miller KD,
 Kim TE, Murren JR. Therapy for stage IIIB and stage IV non-small cell lung cancer. Clin Chest Med. 2002 Mar; 23(1):209-224.
 Sequist LV, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 Sep 20; 31(27):3327-3334.
 Fukuoka M, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in
 Rosell R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar; 13(3):239-246.
 Maemondo M, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010 Jun 24; 362(25):2380-2388.
 Chih-Hsin Yang J et al Afatinib versus cisplatin based chemotherapy for EGFR mutation positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival from two randomized phase 3 trials Lancet Oncology 2015;16 141-151
View original content with multimedia:http://www.prnewswire.com/news-releases/highmark-healths-vital-innovation-program-testing-benefits-of-biocepts-liquid-biopsy-platform-for-improving-outcomes-and-lowering-costs-of-treatment-for-patients-with-non-small-cell-lung-cancer-300701629.html
Janice Maszle, Highmark Health, email@example.com, 412.544.7643, 412.217.7970 (cell); Biocept Media Contact - Colleen Murphy, Trevelino/Keller, firstname.lastname@example.org, 404.214.0722, Ext. 109